These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21738631)

  • 1. A PTG variant contributes to a milder phenotype in Lafora disease.
    Guerrero R; Vernia S; Sanz R; Abreu-Rodríguez I; Almaraz C; García-Hoyos M; Michelucci R; Tassinari CA; Riguzzi P; Nobile C; Sanz P; Serratosa JM; Gómez-Garre P
    PLoS One; 2011; 6(6):e21294. PubMed ID: 21738631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lafora progressive myoclonus epilepsy: NHLRC1 mutations affect glycogen metabolism.
    Couarch P; Vernia S; Gourfinkel-An I; Lesca G; Gataullina S; Fedirko E; Trouillard O; Depienne C; Dulac O; Steschenko D; Leguern E; Sanz P; Baulac S
    J Mol Med (Berl); 2011 Sep; 89(9):915-25. PubMed ID: 21505799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation.
    Fernández-Sánchez ME; Criado-García O; Heath KE; García-Fojeda B; Medraño-Fernández I; Gomez-Garre P; Sanz P; Serratosa JM; Rodríguez de Córdoba S
    Hum Mol Genet; 2003 Dec; 12(23):3161-71. PubMed ID: 14532330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.
    DePaoli-Roach AA; Tagliabracci VS; Segvich DM; Meyer CM; Irimia JM; Roach PJ
    J Biol Chem; 2010 Aug; 285(33):25372-81. PubMed ID: 20538597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG).
    Worby CA; Gentry MS; Dixon JE
    J Biol Chem; 2008 Feb; 283(7):4069-76. PubMed ID: 18070875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin.
    Vernia S; Rubio T; Heredia M; Rodríguez de Córdoba S; Sanz P
    PLoS One; 2009 Jun; 4(6):e5907. PubMed ID: 19529779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early-onset Lafora body disease.
    Turnbull J; Girard JM; Lohi H; Chan EM; Wang P; Tiberia E; Omer S; Ahmed M; Bennett C; Chakrabarty A; Tyagi A; Liu Y; Pencea N; Zhao X; Scherer SW; Ackerley CA; Minassian BA
    Brain; 2012 Sep; 135(Pt 9):2684-98. PubMed ID: 22961547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ppp1r3d deficiency preferentially inhibits neuronal and cardiac Lafora body formation in a mouse model of the fatal epilepsy Lafora disease.
    Israelian L; Nitschke S; Wang P; Zhao X; Perri AM; Lee JPY; Verhalen B; Nitschke F; Minassian BA
    J Neurochem; 2021 Jun; 157(6):1897-1910. PubMed ID: 32892347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of glycogen synthesis by the laforin-malin complex is modulated by the AMP-activated protein kinase pathway.
    Solaz-Fuster MC; Gimeno-Alcañiz JV; Ros S; Fernandez-Sanchez ME; Garcia-Fojeda B; Criado Garcia O; Vilchez D; Dominguez J; Garcia-Rocha M; Sanchez-Piris M; Aguado C; Knecht E; Serratosa J; Guinovart JJ; Sanz P; Rodriguez de Córdoba S
    Hum Mol Genet; 2008 Mar; 17(5):667-78. PubMed ID: 18029386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AMP-activated protein kinase phosphorylates R5/PTG, the glycogen targeting subunit of the R5/PTG-protein phosphatase 1 holoenzyme, and accelerates its down-regulation by the laforin-malin complex.
    Vernia S; Solaz-Fuster MC; Gimeno-Alcañiz JV; Rubio T; García-Haro L; Foretz M; de Córdoba SR; Sanz P
    J Biol Chem; 2009 Mar; 284(13):8247-55. PubMed ID: 19171932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lafora progressive myoclonus epilepsy: recent insights into cell degeneration.
    Spuch C; Ortolano S; Navarro C
    Recent Pat Endocr Metab Immune Drug Discov; 2012 May; 6(2):99-107. PubMed ID: 22369717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycogenic activity of R6, a protein phosphatase 1 regulatory subunit, is modulated by the laforin-malin complex.
    Rubio-Villena C; Garcia-Gimeno MA; Sanz P
    Int J Biochem Cell Biol; 2013 Jul; 45(7):1479-88. PubMed ID: 23624058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The phosphatase activity of laforin is dispensable to rescue Epm2a-/- mice from Lafora disease.
    Gayarre J; Duran-Trío L; Criado Garcia O; Aguado C; Juana-López L; Crespo I; Knecht E; Bovolenta P; Rodríguez de Córdoba S
    Brain; 2014 Mar; 137(Pt 3):806-18. PubMed ID: 24430976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential pattern of glycogen accumulation after protein phosphatase 1 glycogen-targeting subunit PPP1R6 overexpression, compared to PPP1R3C and PPP1R3A, in skeletal muscle cells.
    Montori-Grau M; Guitart M; García-Martínez C; Orozco A; Gómez-Foix AM
    BMC Biochem; 2011 Nov; 12():57. PubMed ID: 22054094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease.
    Tiberia E; Turnbull J; Wang T; Ruggieri A; Zhao XC; Pencea N; Israelian J; Wang Y; Ackerley CA; Wang P; Liu Y; Minassian BA
    J Biol Chem; 2012 Jul; 287(30):25650-9. PubMed ID: 22669944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel EPM2A mutation yields a slow progression form of Lafora disease.
    Garcia-Gimeno MA; Rodilla-Ramirez PN; Viana R; Salas-Puig X; Brewer MK; Gentry MS; Sanz P
    Epilepsy Res; 2018 Sep; 145():169-177. PubMed ID: 30041081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laforin is required for the functional activation of malin in endoplasmic reticulum stress resistance in neuronal cells.
    Zeng L; Wang Y; Baba O; Zheng P; Liu Y; Liu Y
    FEBS J; 2012 Jul; 279(14):2467-78. PubMed ID: 22578008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lafora disease in the Indian population: EPM2A and NHLRC1 gene mutations and their impact on subcellular localization of laforin and malin.
    Singh S; Satishchandra P; Shankar SK; Ganesh S
    Hum Mutat; 2008 Jun; 29(6):E1-12. PubMed ID: 18311786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lafora disease due to EPM2B mutations: a clinical and genetic study.
    Gómez-Abad C; Gómez-Garre P; Gutiérrez-Delicado E; Saygi S; Michelucci R; Tassinari CA; Rodríguez de Córdoba S; Serratosa JM
    Neurology; 2005 Mar; 64(6):982-6. PubMed ID: 15781812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lafora disease.
    Turnbull J; Tiberia E; Striano P; Genton P; Carpenter S; Ackerley CA; Minassian BA
    Epileptic Disord; 2016 Sep; 18(S2):38-62. PubMed ID: 27702709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.